Abstract

Aim & Objective: To assess the efficacy of a new electromotive system for the transcutaneous delivery of verapamil or of hyaluronic acid to improve the symptoms of Peyronie' s disease (PD) in patients with a curvature deformity of < 30° at the beginning of therapy.


Methods & Materials: Sixty-one PD patients were studied. Thirty were randomly assigned to receive verapamil 10 mg/session (Isoptin®, BGP Products, Rome-Italy), (Group 1, median age 56 years, range 49-62), and 31 were randomly assigned to receive hyaluronic acid 8 mg/session (Sinovial®, IBSA, Lodi-Italy) (Group 2, median age 58 years, range 51-56). There were ten sessions, 2 sessions/week for each drug. Each drug was transdermally administered using the hydroelectrophoresis technique and carried out using a Hydro4and apparatus (Swiss4Med SA, Morbio Inferiore, Switzerland). With respect to the efficacy of the drugs studied, the endpoints were: side effects, pain, erectile function, penile deviations and plaque area (cm2) before, and 3 and 6 months after drug administration. The differences were assessed using the Mann-Whitney Rank test (unmatched groups) or using the Wilcoxon Signed Rank test (matched groups). The differences between the groups in terms of side effects were assessed using the chi-square test.


Results: No significant difference emerged among the baseline values of the two groups. Pain, erectile function, plaque area and penile deformity significantly improved in both groups after treatment, but a notably higher improvement occurred in the patients in whom hyaluronic acid was administered. Only a few negligible side effects occurred in the Group 1 patients treated with Verapamil, with no significant difference between the groups.


Conclusion: Administration of both hyaluronic acid and verapamil using the Hydro4and apparatus is a safe and efficient method for PD therapy.


To view the Full-text HTML/PDF/XML, kindly buy for 5$ or Subscribe

Alternatively, you can buy this article on paypal's site (Click here).
Once the payment of 5 USD or 300 INR is done, just add the article number (digits at the end of the link) in the message box post payment and we will send you the full article within 24 hours.



References

  1. Levine LA. The clinical and psychosocial impact of Peyronie's disease. Am J Manag Care. 2013; 19 (Supp 4) : S55-61 .
    PubMed | Google Scholar
  2. Paulis G, Cavallini G. Clinical Evaluation of Natural History of Peyronie's Disease: Our Experience, Old Myths and New Certainties. Inflamm Allergy Drug Targets. 2013; 12 (5) : 341-8 .
    PubMed | Google Scholar
  3. Zorba OU, Sirma S, Ozgon G. Salabas E, Ozbek U, Kadioglu A. Comparison of apoptotic gene expression profiles between Peyronie's disease plaque and tunica albuginea Adv Clin Exp Med. 2012; 21 (5) : 607-14 .
    PubMed | Google Scholar
  4. Lipshultz LI, Goldstein I, Seftel AD, Kaufman GJ, Smith TM, Tursi JP, Burnett AL. Clinical efficacy of collagenase Clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies. BJU Int. 2015; 116 (4) : 650-6 .
    CrossRef | Google Scholar
  5. Favilla V, Russo GI, Zucchi A, Siracusa G, Privitera S, Cimino S, Madonia M, et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study. Andrology. 2017; 5 (4) : 771-775 .
    CrossRef | PubMed | Google Scholar
  6. Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease. Urology. 2007; 69 (5) : 950-4 .
    PubMed | Google Scholar
  7. Kelâmi A. Autophotography in evaluation of functional penile disorders. Urology . 1983; 21 (6) : 628-9 .
    PubMed | Google Scholar
  8. Symptoms, their physiopathology and outpatient clinic practice and diagnosis Maretti C, Cavallini G, Paulis G. In: Peyronie’s disease: a comprehensive guide, 1st Ed. Heidelberg: Springer Berliner Verlag; 2015 .
  9. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain . 1983; 17 (1) : 45-56 .
    PubMed | Google Scholar
  10. Rosen RC, Riley A, Wagner G, Osterloh IH,  Kirkpatrick J,  Mishra A, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology . 1997; 49 (6) : 822-30 .
    PubMed | Google Scholar
  11. Armitage P. Statistical Methods in Medical Research, 2nd edBlackwell Scientific Publishers: Oxford; 1971.
    Google Scholar
  12. Faul F,  Erdfelder E,  Buchner A, Lang AG. Statistical power analyses using G Power tests for correlation and regression analyses. Behav Res Methods. 2009; 41 (4) : 1149-60 .
    CrossRef | Google Scholar
  13. Swiss4med. Hydro4and operating manual. . 2013.
    Google Scholar
  14. Aliperti LA, Mehta A Peyronie's Disease: Intralesional Therapy and Surgical Intervention. Curr Urol Rep. 2016; 17 (9) : 60 .
    CrossRef | Google Scholar
  15. Pires J, Travis M, Ellsworth P. Peyronie' s disease: overview and recent treatment advances. Urol Nurs. 2015; 35 (4) : 164-78 .
    PubMed | Google Scholar
  16. Neuman MG, Nanau RM, Oruña-Sanchez L, Coto G. Hyaluronic Acid and Wound Healing. J Pharm Pharm Sci . 2015; 18 (1) : 53-60 .
  17. Levine LA,  Estrada CR. Intralesional verapamil for the treatment of Peyronie's disease: a review. Int J Impot Res. 2002; 14 (5) : 324-8 .
    PubMed | Google Scholar
  18. Dang G, Matern R, Bivalacqua TJ, Sikka S,  Hellstrom WJ. Intralesional interferon alpha 2B injections for the treatment of Peyronie's disease. South Med J . 2004; 97 (1) : 42-6 .
    PubMed | Google Scholar
  19. Rehman J,  Benet A,  Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology . 1998; 51 (4) : 620-6 .
    PubMed | Google Scholar

Peer Review & Comments